Drugs for Non-Small Cell Lung Cancer Market

List of Tables
Table 1. Drugs for Non-Small Cell Lung Cancer Market Opportunities & Trends in Global Market
Table 2. Drugs for Non-Small Cell Lung Cancer Market Drivers in Global Market
Table 3. Drugs for Non-Small Cell Lung Cancer Market Restraints in Global Market
Table 4. Key Players of Drugs for Non-Small Cell Lung Cancer in Global Market
Table 5. Top Drugs for Non-Small Cell Lung Cancer Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Drugs for Non-Small Cell Lung Cancer Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Companies, 2017-2022
Table 8. Global Companies Drugs for Non-Small Cell Lung Cancer Product Type
Table 9. List of Global Tier 1 Drugs for Non-Small Cell Lung Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Non-Small Cell Lung Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Drugs for Non-Small Cell Lung Cancer Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Drugs for Non-Small Cell Lung Cancer Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Drugs for Non-Small Cell Lung Cancer Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Drugs for Non-Small Cell Lung Cancer Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2023-2028
Table 30. Bristol-Myers Squibb Corporate Summary
Table 31. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 32. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 33. GlaxoSmithKline Corporate Summary
Table 34. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 35. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 36. Menarini Corporate Summary
Table 37. Menarini Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 38. Menarini Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 39. Sanofi Corporate Summary
Table 40. Sanofi Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 41. Sanofi Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 42. Ziopharm Oncology Corporate Summary
Table 43. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 44. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 45. Alchemia Corporate Summary
Table 46. Alchemia Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 47. Alchemia Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 48. Amgen Corporate Summary
Table 49. Amgen Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 50. Amgen Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 51. Apotex Corporate Summary
Table 52. Apotex Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 53. Apotex Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 54. BioMarin Pharmaceutical Corporate Summary
Table 55. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 56. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 57. CellAct Pharma Corporate Summary
Table 58. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 59. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 60. Cerulean Pharma Corporate Summary
Table 61. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 62. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 63. Cipla Corporate Summary
Table 64. Cipla Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 65. Cipla Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 66. Cornerstone Pharmaceuticals Corporate Summary
Table 67. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 68. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 69. Curis Corporate Summary
Table 70. Curis Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 71. Curis Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 72. CytRx Corporate Summary
Table 73. CytRx Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 74. CytRx Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 75. Eli Lilly Corporate Summary
Table 76. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 77. Eli Lilly Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 78. Exelixis Corporate Summary
Table 79. Exelixis Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 80. Exelixis Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 81. Fresenius Kabi Corporate Summary
Table 82. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 83. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 84. Genentech Corporate Summary
Table 85. Genentech Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 86. Genentech Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 87. Hikma Pharmaceuticals Corporate Summary
Table 88. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 89. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 90. Hospira Corporate Summary
Table 91. Hospira Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 92. Hospira Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 93. Intas Pharmaceuticals Corporate Summary
Table 94. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 95. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 96. Karyopharm Therapeutics Corporate Summary
Table 97. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 98. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 99. Kyowa Hakko Kirin Corporate Summary
Table 100. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 101. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
Table 102. Ligand Pharmaceuticals Corporate Summary
Table 103. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Offerings
Table 104. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Drugs for Non-Small Cell Lung Cancer Segment by Type in 2021
Figure 2. Drugs for Non-Small Cell Lung Cancer Segment by Application in 2021
Figure 3. Global Drugs for Non-Small Cell Lung Cancer Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Drugs for Non-Small Cell Lung Cancer Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Drugs for Non-Small Cell Lung Cancer Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drugs for Non-Small Cell Lung Cancer Revenue in 2021
Figure 8. By Type - Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
Figure 9. By Application - Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
Figure 10. By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
Figure 11. By Country - North America Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
Figure 12. US Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
Figure 16. Germany Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 17. France Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
Figure 24. China Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 28. India Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
Figure 30. Brazil Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
Figure 33. Turkey Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Drugs for Non-Small Cell Lung Cancer Revenue, (US$, Mn), 2017-2028
Figure 37. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Menarini Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Sanofi Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Alchemia Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Amgen Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Apotex Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Cipla Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Curis Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. CytRx Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Eli Lilly Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Exelixis Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. Genentech Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 57. Hospira Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 58. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 59. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 60. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 61. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)